Department of Vitreoretinal Surgery, Moorfields Eye Hospital, NHS Foundation Trust, London, UK.
Eye (Lond). 2018 Mar;32(3):597-601. doi: 10.1038/eye.2017.261. Epub 2017 Dec 8.
PurposeTo investigate long-term visual acuity (VA) outcomes and complication rates in vitrectomised eyes undergoing anterior chamber intraocular lens (ACIOL) insertion.Patients and methodsA single-centre, retrospective case series including all patients who had undergone ACIOL placement at the time of vitrectomy surgery or having had previous vitrectomy, between January 2007 and January 2013. Patients were identified using an electronic database and paper casefile notes were analysed for all patients. Patients were excluded if they had <3 months follow-up.ResultsTwo hundred and seventy-one patients were included in the analysis. Mean follow-up was 27 months. One hundred and forty-eight patients were vitrectomised before ACIOL placement. One hundred and twenty-three patients underwent vitrectomy at the time of ACIOL placement. Mean best-corrected visual acuity (BCVA) before ACIOL placement was 1.27 LogMar (SD 0.95). Mean BCVA at final follow-up was 0.51 LogMar (SD 0.66) (paired-sample T-test P<0.001). Forty (15%) patients developed postoperative cystoid macular oedema (CMO). Eighty-seven (32%) patients had an intraocular pressure (IOP) rise acutely post ACIOL insertion. Fifteen (6%) patients developed corneal decompensation. Five subsequently required corneal grafting. Sixteen patients had ACIOL displacement or instability requiring further surgery.ConclusionsACIOL insertion after vitrectomy is effective. Ninety-two per cent of patients maintained or gained VA, comparable to previous studies of ACIOL insertion post complicated cataract surgery. Raised IOP was the most frequent complication: 61 patients were on topical therapy at most recent follow-up. CMO tended to be acute. Corneal decompensation was infrequent.
探讨玻璃体切除术后行前房人工晶状体(ACIOL)植入的长期视力(VA)结果和并发症发生率。
这是一项单中心回顾性病例系列研究,纳入了 2007 年 1 月至 2013 年 1 月期间在玻璃体切除手术时或之前已行玻璃体切除手术的患者中行 ACIOL 植入术的患者。使用电子数据库识别患者,并对所有患者的病历记录进行分析。如果患者的随访时间<3 个月,则将其排除在外。
271 例患者纳入分析。平均随访时间为 27 个月。148 例患者在 ACIOL 植入前行玻璃体切除术,123 例患者在 ACIOL 植入时行玻璃体切除术。ACIOL 植入前最佳矫正视力(BCVA)平均为 1.27 LogMAR(SD 0.95),最终随访时平均 BCVA 为 0.51 LogMAR(SD 0.66)(配对样本 T 检验 P<0.001)。40 例(15%)患者术后发生黄斑囊样水肿(CME),87 例(32%)患者 ACIOL 植入后急性眼压升高,15 例(6%)患者发生角膜失代偿,其中 5 例随后需要角膜移植,16 例患者 ACIOL 移位或不稳定需要进一步手术。
玻璃体切除术后行 ACIOL 植入术效果良好。92%的患者保持或提高了视力,与先前复杂白内障手术后行 ACIOL 植入术的研究结果相当。最常见的并发症是眼压升高:61 例患者在最近一次随访时仍在接受局部治疗。CME 往往是急性的,角膜失代偿很少见。